Repare Therapeutics (RPTX) AI Stock Analysis

• Market Cap: $77.76M
• Dividend Yield: N/A
• Average Volume (3M): 92.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: -99.64%
• EPS Growth: -59.17%
• Country: US
• Employees: 129
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 42,959,170
• 10 Day Avg. Volume: 96,335
• 30 Day Avg. Volume: 92,328
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.63
• Enterprise Value/Revenue: -0.92
• Enterprise Value/Gross Profit: -1.27
• Enterprise Value/Ebitda: 0.44
• 1Y Price Target: $1.50
• Price Target Upside: -17.13% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 60 Neutral
• Price Target: $1.50 ▼(-17.13% Downside)

Repare Therapeutics' overall stock score of 60 is driven by moderate technical momentum and a positive corporate event, which offset financial challenges. The licensing deal provides strategic advantages, while technical indicators suggest short-term strength. However, ongoing financial losses and valuation concerns temper the stock's attractiveness.

Positive Factors

Strategic Partnerships

The licensing deal with Debiopharm provides immediate financial benefits and supports Repare's strategic focus on advancing clinical priorities, enhancing long-term growth prospects.

Cash Position

A robust cash position and low leverage provide financial stability and flexibility, allowing Repare to continue investing in R&D and strategic initiatives.

Innovative Business Model

Repare's innovative approach in precision oncology using CRISPR technology positions it well to address unmet medical needs, potentially leading to breakthrough therapies.

Negative Factors

Revenue Volatility

Significant revenue volatility indicates challenges in achieving consistent financial performance, which may affect long-term sustainability and investor confidence.

Operating Losses

Ongoing operating losses reflect operational inefficiencies and impact profitability, posing a risk to Repare's ability to sustain operations without external funding.

Negative Cash Flow

Negative cash flow from operations suggests that Repare is not generating enough cash to cover expenses, potentially limiting its ability to invest in growth opportunities.

Repare Therapeutics Business Overview & Revenue Model

Company Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

How the Company Makes Money

Repare Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies that are interested in co-developing its drug candidates. The company may receive upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of any products that result from these partnerships. Additionally, Repare may engage in strategic licensing agreements, allowing other firms to develop or commercialize its technologies, further contributing to its revenue streams. Research grants and funding from government or non-profit organizations aimed at supporting cancer research may also play a role in its financial model.

Repare Therapeutics Financial Statement Overview

Summary

Repare Therapeutics faces significant financial challenges, with consistent losses and revenue volatility. The income statement indicates operational inefficiencies, while the balance sheet shows stability with a strong cash position and low leverage. Despite negative cash flow from operations, the company maintains robust liquidity, providing a buffer for future improvements.

Income Statement

Repare Therapeutics has shown significant revenue volatility over the years, with revenue dropping to zero in the most recent period from $51.13 million the previous year and $131.83 million two years prior. The company has consistently incurred operating losses, and negative net income, indicating ongoing profitability challenges. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies. However, the company showed a brief revenue surge in 2022, which might indicate potential for recovery.

Balance Sheet

The company maintains a strong equity base relative to its liabilities, reflected in a low Debt-to-Equity ratio, which suggests stability. Despite consistent net losses, Repare's cash position remains robust, indicating prudent cash management. However, the Return on Equity is negative due to sustained net losses, which impacts overall shareholder returns negatively. The equity ratio has shown some decline but remains relatively healthy.

Cash Flow

Repare Therapeutics has faced challenges with negative free cash flow, although the cash flow from investing activities has been positive, largely due to asset management. The operating cash flow remains negative, indicating that the company is not generating enough cash from core operations to cover expenses. However, the company has managed to sustain cash reserves, which provides liquidity to continue operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	53.73M	53.48M	51.13M	131.83M	7.60M	135.00K
Gross Profit	38.71M	40.10M	37.89M	15.11M	-80.25M	-1.65M
EBITDA	-112.66M	-90.22M	-114.27M	-17.82M	-107.19M	-53.41M
Net Income	-109.86M	-84.69M	-93.80M	-29.05M	-106.91M	-53.42M
Balance Sheet
Total Assets	130.49M	176.51M	253.90M	364.07M	368.71M	357.09M
Cash, Cash Equivalents and Short-Term Investments	109.47M	152.79M	223.63M	343.94M	341.87M	333.71M
Total Debt	649.00K	1.93M	3.41M	5.43M	7.31M	4.00M
Total Liabilities	20.09M	25.38M	41.82M	84.56M	80.29M	70.26M
Stockholders Equity	110.41M	151.13M	212.08M	279.52M	288.42M	286.83M
Cash Flow
Free Cash Flow	-103.34M	-76.44M	-129.10M	-280.00K	-87.49M	-8.32M
Operating Cash Flow	-103.34M	-76.44M	-127.16M	322.00K	-85.80M	-6.08M
Investing Cash Flow	90.87M	49.47M	78.04M	-175.78M	-1.68M	-9.76M
Financing Cash Flow	246.00K	542.00K	842.00K	880.00K	95.56M	247.84M

Repare Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.81
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPTX, the sentiment is Positive. The current price of 1.81 is above the 20-day moving average (MA) of 1.64, above the 50-day MA of 1.57, and above the 200-day MA of 1.49, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 77.83 is Negative, neither overbought nor oversold. The STOCH value of 92.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RPTX.

Repare Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	60 Neutral	$77.76M	―	-69.96%	―	-99.64%	-59.17%
STTK	55 Neutral	$94.85M	―	-73.39%	―	-27.33%	34.66%
XLO	54 Neutral	$37.82M	―	-277.74%	―	536.44%	63.68%
Sector *	51 Neutral	$8.02B	-0.39	-43.38%	2.20%	22.34%	-2.13%
SPRO	48 Neutral	$109.74M	10.83	-94.59%	―	-67.67%	-390.60%
OKUR	42 Neutral	$33.82M	―	-90.56%	―	―	68.13%
PRLD	35 Underperform	$67.35M	―	-96.33%	―	―	7.72%

Repare Therapeutics Corporate Events

Repare Therapeutics Signs Licensing Deal with Debiopharm

On July 15, 2025, Repare Therapeutics entered into an exclusive worldwide license agreement with Debiopharm International for the development and commercialization of lunresertib, a PKMYT1 inhibitor. The agreement grants Debiopharm rights to develop and market products containing lunresertib, either alone or in combination with Debio 0123. Repare will receive a $10 million upfront payment and potentially up to $257 million in milestone payments, along with royalties on global sales. This collaboration builds on their previous partnership and allows Debiopharm to assume responsibility for the ongoing MYTHIC clinical trial. The deal supports Repare’s focus on advancing its clinical priorities, particularly the ongoing Phase 1 trials for RP-3467 and RP-1664, with data expected in the latter half of 2025.

Repare Therapeutics Updates Severance Benefits for Executives

On June 13, 2025, Repare Therapeutics Inc.’s Compensation Committee approved amendments to the severance benefits for certain officers, including Executive Vice President and Chief Scientific Officer Michael Zinda. These amendments provide Dr. Zinda with specific severance benefits if his employment is terminated without cause or if he resigns for good reason, not linked to a change in control. This decision reflects the company’s commitment to ensuring competitive compensation packages for its executives, potentially impacting its operational stability and stakeholder confidence.

Repare Therapeutics Holds Annual Shareholder Meeting

On June 17, 2025, Repare Therapeutics held its Annual Meeting of Shareholders, where key decisions were made. Shareholders elected four directors to the board, approved executive compensation on a non-binding basis, and appointed Ernst & Young LLP as the independent registered public accounting firm for 2025.